Cytek Biosciences, Inc. (CTKB) Misses Q2 EPS by 4c

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q2 EPS of ($0.03), $0.04 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $49.69 million versus the consensus estimate of $45.71 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• Ciena beats estimates on strong AI-driven demand, shares rise
• MediaAlpha names new CFO and raises Q3 2026 guidance
• Alight names Bruce Wolfe as SVP, Wealth Solution Leader